Nanotechnology in Radiation Oncology

Bo Sun; C. Tilden Hagan; Joseph Caster; Andrew Z. Wang

doi:10.1016/j.hoc.2019.08.002

Nanotechnology in Radiation Oncology

Bo Sun, C. Tilden Hagan, Joseph Caster, Andrew Z. Wang

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Nanotechnology has made remarkable contributions to clinical oncology. Nanotherapeutics and diagnostic tools have distinctive characteristics which allow them superior abilities to deliver therapeutics and imaging agents for radiation oncology. Compared to solid biopsies and imaging, the analysis of circulating tumor cells (CTCs) offers a more rapid, real-time, and less invasive method to monitor the dynamic molecular profiles of tumors. The potential of CTCs to be translated as a novel cancer biomarker has been demonstrated in numerous clinical studies. This review will discuss clinical applications of nanomaterials in radiation oncology and the implication of CTCs in cancer detection and monitoring.

Original language	English (US)
Pages (from-to)	1071-1093
Number of pages	23
Journal	Hematology/Oncology Clinics of North America
Volume	33
Issue number	6
DOIs	https://doi.org/10.1016/j.hoc.2019.08.002
State	Published - Dec 2019
Externally published	Yes

Keywords

Cancer biomarkers
Circulating tumor DNA
Circulating tumor cells
Liquid biopsy
Nanoparticles
Radiosensitization
Radiotherapy
Tumor imaging

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2019.08.002

Cite this

@article{2616ecdb855f4337b57c9f4f1a969a9e,

title = "Nanotechnology in Radiation Oncology",

abstract = "Nanotechnology has made remarkable contributions to clinical oncology. Nanotherapeutics and diagnostic tools have distinctive characteristics which allow them superior abilities to deliver therapeutics and imaging agents for radiation oncology. Compared to solid biopsies and imaging, the analysis of circulating tumor cells (CTCs) offers a more rapid, real-time, and less invasive method to monitor the dynamic molecular profiles of tumors. The potential of CTCs to be translated as a novel cancer biomarker has been demonstrated in numerous clinical studies. This review will discuss clinical applications of nanomaterials in radiation oncology and the implication of CTCs in cancer detection and monitoring.",

keywords = "Cancer biomarkers, Circulating tumor DNA, Circulating tumor cells, Liquid biopsy, Nanoparticles, Radiosensitization, Radiotherapy, Tumor imaging",

author = "Bo Sun and Hagan, {C. Tilden} and Joseph Caster and Wang, {Andrew Z.}",

note = "Funding Information: This work was supported by funding from National Institutes of Health/National Cancer Institute ( U54CA198999 and R01 EB25651 ), Department of Defense ( W81XWH-16-1-0530 ), and The University of North Carolina's Research Opportunities Initiative grant. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = dec,

doi = "10.1016/j.hoc.2019.08.002",

language = "English (US)",

volume = "33",

pages = "1071--1093",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Nanotechnology in Radiation Oncology

AU - Sun, Bo

AU - Hagan, C. Tilden

AU - Caster, Joseph

AU - Wang, Andrew Z.

N1 - Funding Information: This work was supported by funding from National Institutes of Health/National Cancer Institute ( U54CA198999 and R01 EB25651 ), Department of Defense ( W81XWH-16-1-0530 ), and The University of North Carolina's Research Opportunities Initiative grant. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/12

Y1 - 2019/12

N2 - Nanotechnology has made remarkable contributions to clinical oncology. Nanotherapeutics and diagnostic tools have distinctive characteristics which allow them superior abilities to deliver therapeutics and imaging agents for radiation oncology. Compared to solid biopsies and imaging, the analysis of circulating tumor cells (CTCs) offers a more rapid, real-time, and less invasive method to monitor the dynamic molecular profiles of tumors. The potential of CTCs to be translated as a novel cancer biomarker has been demonstrated in numerous clinical studies. This review will discuss clinical applications of nanomaterials in radiation oncology and the implication of CTCs in cancer detection and monitoring.

AB - Nanotechnology has made remarkable contributions to clinical oncology. Nanotherapeutics and diagnostic tools have distinctive characteristics which allow them superior abilities to deliver therapeutics and imaging agents for radiation oncology. Compared to solid biopsies and imaging, the analysis of circulating tumor cells (CTCs) offers a more rapid, real-time, and less invasive method to monitor the dynamic molecular profiles of tumors. The potential of CTCs to be translated as a novel cancer biomarker has been demonstrated in numerous clinical studies. This review will discuss clinical applications of nanomaterials in radiation oncology and the implication of CTCs in cancer detection and monitoring.

KW - Cancer biomarkers

KW - Circulating tumor DNA

KW - Circulating tumor cells

KW - Liquid biopsy

KW - Nanoparticles

KW - Radiosensitization

KW - Radiotherapy

KW - Tumor imaging

UR - http://www.scopus.com/inward/record.url?scp=85072741089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072741089&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2019.08.002

DO - 10.1016/j.hoc.2019.08.002

M3 - Review article

C2 - 31668207

AN - SCOPUS:85072741089

SN - 0889-8588

VL - 33

SP - 1071

EP - 1093

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 6

ER -

Nanotechnology in Radiation Oncology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this